Mission Bio, a US-based precision medicine and genomics spinout from University of California, San Francisco (UCSF), closed a $10m series A round yesterday backed by the Stanford University-affiliated Stanford-Start X fund.
The round was led by venture capital firm Mayfield Fund, with contributions from angel investment vehicles Keiretsu Forum, Tech Coast Angels and Life Science Angels.
Mission Bio has created a genomics-based analytics platform called Tapestri that has the potential to process as many as 10,000 cells while distinguishing each individually.
The technology is based on research by Adam Abate, an associate professor in UCSF’s Department of Bioengineering and Therapeutic Sciences.
The funding will go towards launching Tapestri with an application designed to assess acute myeloid leukaemia. Clients from Stanford University School of Medicine and University of Texas’s MD Anderson Cancer Centre are currently piloting the platform.
Life Science Angels had earlier injected an undisclosed amount of seed funding in February 2017.
Charlie Silver, CEO of Mission Bio, said: “Delivering the right medicine to every diseased cell in a patient requires an understanding of the complex cell-to-cell variations that drive disease.
“We believe that Tapestri’s novel capability for scalable single-cell DNA analysis will enable the development and delivery of precision medicine based on the unique genomic profile of each patient.”
